Jean‐Philippe Guégan

Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

Lucile Vanhersecke, Maxime Brunet, Jean‐Philippe Guégan et al. · Nature Cancer · 2021 · 569 citations · Full text

Life Sciences, Immunology, Oncology +17

Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort

Antoîne Italiano, Alban Bessede, M. Pulido et al. · Nature Medicine · 2022 · 263 citations

Medicine, Immunology, Oncology +13

Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial

Sophie Cousin, Coralie Cantarel, Jean‐Philippe Guégan et al. · Clinical Cancer Research · 2021 · 153 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies

Mathieu Larroquette, Jean‐Philippe Guégan, Benjamin Besse et al. · Journal for ImmunoTherapy of Cancer · 2022 · 148 citations · Full text

Medicine, Immunology, Oncology +17

Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance

Yohann Loriot, Aurélien Marabelle, Jean‐Philippe Guégan et al. · Annals of Oncology · 2021 · 87 citations · Full text

Life Sciences, Immunology, Oncology +17